SGLT-2i and ARB Combination Therapy in Patients With T2DM and Nocturnal Hypertension (SACRA Study)
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 174 participants.
Also called NCT03050229
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 174 participants
- Registry
-
NCT03050229
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Japan
- Registry status
- Completed
Technical summary
Registry record NCT03050229. Randomized; quadruple masking; primary purpose treatment. Start 2017-01 (actual); primary completion 2017-10 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- SGLT-2i and ARB Combination Therapy in Patients With T2DM and Nocturnal Hypertension (SACRA Study)
- Condition
- Nocturnal Hypertension
- Condition
- T2DM (Type 2 Diabetes Mellitus)
- Intervention (Drug)
- Empagliflozin
- Intervention (Drug)
- Placebo
- Lead sponsor
- Jichi Medical University
- Collaborator
- Boehringer Ingelheim
- Collaborator
- Eli Lilly and Company
Record details
- Record id
cardio:ct-nct03050229- Content hash
dc57d9df85239e6b134c19e697b54ec8c182f0499ae31da435c1eaf8f581e883